EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells

The hallmarks of cancer

Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219

Molecular portraits of human breast tumours

Perou, C., Sørlie, T., Eisen, M., van de Rijn, M., Jeffrey, S., Rees, C. A., Pollack, J., Ross, D., Johnsen, H., Akslen, L., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,551

Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer

Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,239

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

Sørlie, T., Perou, C. M., Tibshirani, R. J., Aas, T., Geisler, S. B., Johnsen, H., Hastie, T. J., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 11,506

Gene expression profiling predicts clinical outcome of breast cancer

van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536

Ki67 expression in breast cancer

Elkablawy, M. A., Albasri, A. M., Mohammed, R. A., Hussainy, A. S., Nouh, M. M., & Alhujaily, A. S. (2016) · Saudi Medical Journal · doi:10.15537/smj.2016.2.12285 · Cited by 4,382

Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing

Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P., Jones, R. S., & Zhang, Y. (2002) · Science · doi:10.1126/science.1076997 · Cited by 3,775

Cancer Statistics, 2003

Jemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E., & Thun, M. J. (2003) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.53.1.5 · Cited by 3,275

The polycomb group protein EZH2 is involved in progression of prostate cancer

Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717

Diseases of the Breast

Haagenson, C. (1971) · Cited by 1,773

EZH2–CCF–cGAS Axis Promotes Breast Cancer Metastasis

Duan, D., Shang, M., Han, Y., Liu, J., Liu, J., Kong, S. H., Hou, J., Huang, B., Lü, J., & Zhang, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031788 · Cited by 37

Polycomb Directed Cell Fate Decisions in Development and Cancer

German, B., & Ellis, L. (2022) · Epigenomes · doi:10.3390/epigenomes6030028 · Cited by 34

EphB6 Receptor Modulates Micro RNA Profile of Breast Carcinoma Cells

Bhushan, L., & Kandpal, R. P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022484 · Cited by 37

Epigenetic Cancer Prevention Mechanisms in Skin Cancer

Saha, K., Hornyak, T. J., & Eckert, R. L. (2013) · The AAPS Journal · doi:10.1208/s12248-013-9513-3 · Cited by 36

Mutation Spectra of Histone Methyltransferases With Canonical SET Domains and EZH2-Targeted Therapy

Katoh, M. (2015) · Epigenomics · doi:10.2217/epi.15.89 · Cited by 36

Functional characterization of EZH2β reveals the increased complexity of EZH2 isoforms involved in the regulation of mammalian gene expression

Grzenda, A. L., Lomberk, G. A., Svingen, P. A., Mathison, A., Calvo, E. L., Iovanna, J., Xiong, Y., Faubion, W. A., & Urrutia, R. A. (2013) · Epigenetics & Chromatin · doi:10.1186/1756-8935-6-3 · Cited by 36

Role of bacterial infection in the epigenetic regulation of Wnt antagonist WIF1 by PRC2 protein EZH2

Roy, B. C., Subramaniam, D., Ahmed, I., Jala, V. R., Hester, C. M., Greiner, K. A., Haribabu, B., Anant, S., & Umar, S. (2014) · Oncogene · doi:10.1038/onc.2014.386 · Cited by 35

High-Level Expression of RIPK4 and EZH2 Contributes to Lymph Node Metastasis and Predicts Favorable Prognosis in Patients With Cervical Cancer

Azizmohammadi, S., Azizmohammadi, S., Safari, A., Kaghazian, M., Sadrkhanlo, M., Behnod, V., & Seifoleslami, M. (2016) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504016x14749735594687 · Cited by 35

Trichostatin A activates FOXO1 and induces autophagy in osteosarcoma

Bai, Y.-J., Chen, Y., Chen, X., Jiang, J.-K., Wang, X., Wang, L., Wang, J., Zhang, J., & Gao, L. (2018) · Archives of Medical Science · doi:10.5114/aoms.2018.73860 · Cited by 35

Breast cancer risk in premalignant lesions: osteopontin splice variants indicate prognosis

Walaszek, K., Lower, E. E., Ziolkowski, P. P., & Weber, G. F. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0228-1 · Cited by 35

Both EZH2 and JMJD6 regulate cell cycle genes in breast cancer

Biswas, A., Mukherjee, G., Kondaiah, P., & Desai, K. V. (2020) · BMC Cancer · doi:10.1186/s12885-020-07531-8 · Cited by 35

Canonical and non-canonical roles of the histone methyltransferase EZH2 in mammary development and cancer

Bae, W. K., & Hennighausen, L. G. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.05.002 · Cited by 35

The Polycomb group protein Enhancer of Zeste 2: its links to DNA repair and breast cancer

Zeidler, M. G., & Kleer, C. G. (2006) · Journal of Molecular Histology · doi:10.1007/s10735-006-9042-9 · Cited by 35

Enhancer of zeste homolog 2 (EZH2) in pediatric soft tissue sarcomas: first implications

Ciarapica, R., Miele, L., Giordano, A., Locatelli, F., & Rota, R. (2011) · BMC Medicine · doi:10.1186/1741-7015-9-63 · Cited by 35

Overexpression of enhancer of zeste homolog 2 and MUC1 may be related to malignant behaviour in intraductal papillary neoplasm of the bile duct

Sasaki, M., Matsubara, T., Yoneda, N., Nomoto, K., Tsuneyama, K., Sato, Y., & Nakanuma, Y. (2012) · Histopathology · doi:10.1111/his.12016 · Cited by 36

Chromatin‐modifying proteins in cancer

Fog, C. K., Jensen, K. T., & Lund, A. H. (2007) · Apmis · doi:10.1111/j.1600-0463.2007.apm_776.xml.x · Cited by 35

Molecular and Cellular Changes During Cancer Progression Resulting From Genetic and Epigenetic Alterations

Pruitt, K. (2016) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2016.09.001 · Cited by 37

Carcinoma of the Breast With Medullary-like Features: Diagnostic Challenges and Relationship With BRCA1 and EZH2 Functions

Kleer, C. G. (2009) · Archives of Pathology & Laboratory Medicine · doi:10.5858/133.11.1822 · Cited by 34

Aberrant Upregulation of 14-3-3σ and EZH2 Expression Serves as an Inferior Prognostic Biomarker for Hepatocellular Carcinoma

Zhang, Y., Li, Y., Lin, C., Ding, J., Liao, G., & Tang, B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107251 · Cited by 34

Integrative Analysis of Normal Long Intergenic Non-Coding RNAs in Prostate Cancer

Bawa, P., Zackaria, S., Verma, M. K., Gupta, S., Raghunathan, S., Chaudhary, B., & Srinivasan, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0122143 · Cited by 34

Development of a high-throughput fluorescence polarization assay for the discovery of EZH2-EED interaction inhibitors

Zhu, M.-R., Du, D., Hu, J., Li, L., Liu, J.-Q., Ding, H., Kong, X., Jiang, H., Chen, K., & Luo, C. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.59 · Cited by 34

Expression of the polycomb group protein EZH2 and its relation to outcome in patients with urothelial carcinoma of the bladder

Hinz, S., Kempkensteffen, C., Christoph, F., Hoffmann, M. J., Krause, H., Schrader, M. G., Schostak, M., Miller, K., & Weikert, S. (2007) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-007-0288-8 · Cited by 34

Six-transmembrane epithelial antigen of the prostate and enhancer of zeste homolog 2 as immunotherapeutic targets for lung cancer

Hayashi, S., Kumai, T., Matsuda, Y., Aoki, N., Sato, K., Kimura, S., Kitada, M., Tateno, M., Celis, E., & Kobayashi, H. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-191 · Cited by 34

The relationship between the expression of USP22, BMI1, and EZH2 in hepatocellular carcinoma and their impacts on prognosis

Zhai, R., Tang, F., Gong, J., Zhang, J., Lei, B., Li, B., Wei, Y., Liang, X., Tang, B., & He, S. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s110985 · Cited by 35

Epigenome programming by Polycomb and Trithorax proteins

Cernilogar, F. M., & Orlando, V. (2005) · Biochemistry and Cell Biology · doi:10.1139/o05-040 · Cited by 34

Emerging roles of epithelial-mesenchymal plasticity in invasion-metastasis cascade and therapy resistance

Garg, M. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-10003-5 · Cited by 33

EZH2 expression is a prognostic factor in childhood intracranial ependymoma: A Canadian Pediatric Brain Tumor Consortium study

Li, A. M., Dunham, C. P., Tabori, U. Y., Carret, A., McNeely, P. D., Johnston, D. L., Lafay‐Cousin, L., Wilson, B. A., Eisenstat, D. D., Jabado, N., et al. (2015) · Cancer · doi:10.1002/cncr.29198 · Cited by 33

Regulators of gene expression as biomarkers for prostate cancer.

Willard, S. S., & Koochekpour, S. (2012) · PubMed Central · Cited by 34

Lysine methylation in cancer: SMYD3‐MAP3K2 teaches us new lessons in the Ras‐ERK pathway

Colón‐Bolea, P., & Crespo, P. (2014) · BioEssays · doi:10.1002/bies.201400120 · Cited by 33

Impact of OGT deregulation on EZH2 target genes FOXA1 and FOXC1 expression in breast cancer cells

Forma, E., Jóźwiak, P., Ciesielski, P., Zaczek, A., Starska, K., Bryś, M., & Krześlak, A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0198351 · Cited by 33

EZH2 Contributes To Cisplatin Resistance In Breast Cancer By Epigenetically Suppressing miR-381 Expression

Dou, D., Ge, X. Q., Wang, X., Xu, X., Zhang, Z., Jingjing, S., Cao, Z., Gu, Y., & Han, M. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s214104 · Cited by 33

NEDD4 Plays Roles in the Maintenance of Breast Cancer Stem Cell Characteristics

Jeon, S., Kim, D., Lee, D.-B., & Cho, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01680 · Cited by 33

Effects of Inflammation on the Immune Microenvironment in Gastric Cancer

Zhao, W., Liu, M., Zhang, M., Wang, Y., Zhang, Y., Wang, S., & Zhang, N. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.690298 · Cited by 33

Histone Methylases and Demethylases Regulating Antagonistic Methyl Marks: Changes Occurring in Cancer

Taylor‐Papadimitriou, J., & Burchell, J. (2022) · Cells · doi:10.3390/cells11071113 · Cited by 34

Hydrophobic tag tethering degrader as a promising paradigm of protein degradation: Past, present and future perspectives

Ha, S., Zhu, J., Xiang, H., & Luo, G. (2023) · Chinese Chemical Letters · doi:10.1016/j.cclet.2023.109192 · Cited by 34

Epigenetic alterations of the keratin 13 gene in oral squamous cell carcinoma

Naganuma, K., Hatta, M., Ikebe, T., & Yamazaki, J. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-988 · Cited by 33

Transcriptional and epigenetic networks in haematological malignancy

Cheung, N., & So, C. W. E. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.03.068 · Cited by 36

EZH2 protein expression in normal breast epithelium and risk of breast cancer: results from the Nurses’ Health Studies

de Beça, F. F., Kensler, K. H., Glass, B., Schnitt, S. J., Tamimi, R. M., & Beck, A. H. (2017) · Breast Cancer Research · doi:10.1186/s13058-017-0817-6 · Cited by 33

Interaction of EZH2 and P65 is involved in the arsenic trioxide-induced anti-angiogenesis in human triple-negative breast cancer cells

Jiang, F., Li, Y., Si, L., Zhang, Z., & Li, Z. (2019) · Cell Biology and Toxicology · doi:10.1007/s10565-018-09458-0 · Cited by 33

Transient requirements of YY1 expression for PcG transcriptional repression and phenotypic rescue

Srinivasan, L., Pan, X., & Atchison, M. L. (2005) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20562 · Cited by 35

Characterization of BRCAA1 and Its Novel Antigen Epitope Identification

Cui, D., Jin, G., Gao, T., Sun, T., Tian, F., Estrada, G. G., Gao, H., & Sarai, A. (2004) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.1136.13.7 · Cited by 33

High expressions of histone methylation- and phosphorylation-related proteins are associated with prognosis of oral squamous cell carcinoma in male population of Taiwan

Chen, J., Yeh, K., Yang, Y.-M., Chang, J., Lee, H.-E., & Hung, S. (2013) · Medical Oncology · doi:10.1007/s12032-013-0513-z · Cited by 32

Context-specific regulation of cancer epigenomes by histone and transcription factor methylation

Sarris, M. E., Nikolaou, K., & Talianidis, I. (2013) · Oncogene · doi:10.1038/onc.2013.87 · Cited by 33

Fuse-binding protein 1 is a target of the EZH2 inhibitor GSK343, in osteosarcoma cells

Xiong, X., Zhang, J.-L., Liang, W., Cao, W., Qin, S., Dai, L., Ye, D., & Liu, Z. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3541 · Cited by 32

Over expression of miR-200c suppresses invasion and restores methotrexate sensitivity in lung cancer A549 cells

Shan, W., Zhang, X., Li, M., Deng, F., & Zhang, J. (2016) · Gene · doi:10.1016/j.gene.2016.07.038 · Cited by 33

EZH2 upregulates the PI3K/AKT pathway through IGF1R and MYC in clinically aggressive chronic lymphocytic leukaemia

Kosalai, S. T., Morsy, M. H. A., Papakonstantinou, N., Mansouri, L., Stavroyianni, N., Kanduri, C., Σταματόπουλος, Κ., Rosenquist, R., & Kanduri, M. (2019) · Epigenetics · doi:10.1080/15592294.2019.1633867 · Cited by 32

GSK343 induces programmed cell death through the inhibition of EZH2 and FBP1 in osteosarcoma cells

Xiong, X., Zhang, J., Li, A., Dai, L., Qin, S., Wang, P., Liu, W., Zhang, Z., Li, X., & Liu, Z. (2019) · Cancer Biology & Therapy · doi:10.1080/15384047.2019.1680061 · Cited by 32

Treating lymphoma is now a bit EZ-er

Morin, R. D., Arthur, S. E., & Assouline, S. E. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020002773 · Cited by 34

Easy or Not—The Advances of EZH2 in Regulating T Cell Development, Differentiation, and Activation in Antitumor Immunity

Huang, J., Zhang, J., Guo, Z., Li, C., Tan, Z. W., Wang, J., Yang, J., & Xue, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.741302 · Cited by 33

Discovery of IHMT-EZH2-115 as a Potent and Selective Enhancer of Zeste Homolog 2 (EZH2) Inhibitor for the Treatment of B-Cell Lymphomas

Zhou, B., Liang, X., Mei, H., Qi, S., Jiang, Z., Wang, A., Zou, F., Liu, Q., Liu, J., Wang, W., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01154 · Cited by 32

Papillary hyperplasia of the gallbladder in pancreaticobiliary maljunction represents a senescence-related lesion induced by lysolecithin

Yamaguchi, J., Sasaki, M., Harada, K., Zen, Y., Sato, Y., Ikeda, H., Itatsu, K., Yokoyama, Y., Ando, H., Ohta, T., et al. (2009) · Laboratory Investigation · doi:10.1038/labinvest.2009.65 · Cited by 34

The expression and significance of the enhancer of zeste homolog 2 in lung adenocarcinoma

Zhang, J. (2012) · Oncology Reports · doi:10.3892/or.2012.1787 · Cited by 32

Induction of aberrant trimethylation of histone H3 lysine 27 by inflammation in mouse colonic epithelial cells

Takeshima, H., Ikegami, D., Wakabayashi, M., Niwa, T., Kim, Y.-J., & Ushijima, T. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs294 · Cited by 32

Premalignant Breast Neoplasia: A Paradigm of Interlesional and Intralesional Molecular Heterogeneity and Its Biological and Clinical Ramifications

Berman, H. K., Gauthier, M. L., & Tlsty, T. D. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0073 · Cited by 33

Quantitative Histone Mass Spectrometry Identifies Elevated Histone H3 Lysine 27 (Lys27) Trimethylation in Melanoma

Sengupta, D., Byrum, S. D., Avaritt, N. L., Davis, L., Shields, B. D., Mahmoud, F. A., Reynolds, M., Orr, L. D., Mackintosh, S. G., Shalin, S. C., et al. (2016) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m115.053363 · Cited by 32

The role of EZH2 in overall survival of colorectal cancer: a meta-analysis

Vilorio-Marqués, L., Martín, V., Diez‐Tascón, C., González-Sevilla, M. F., Fernández‐Villa, T., Honrado, E., Dávila‐Batista, V., & Molina, A. J. (2017) · Scientific Reports · doi:10.1038/s41598-017-13670-z · Cited by 32

Nicotine associated breast cancer in smokers is mediated through high level of EZH2 expression which can be reversed by methyltransferase inhibitor DZNepA

Kumari, K., Das, B., Adhya, A. K., Chaudhary, S., Senapati, S., & Mishra, S. K. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0224-z · Cited by 32

Overexpression of enhance of Zeste homolog 2 (EZH2) in endometrial carcinoma: An NRG Oncology/Gynecologic Oncology Group Study

Krill, L. S., Deng, W., Eskander, R. N., Mutch, D. G., Zweizig, S., Hoang, B. H., Ioffe, O. B., Randall, L. M., Lankes, H. A., Miller, D. S., et al. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.12.003 · Cited by 34

The Polycomb group protein RING1B is overexpressed in ductal breast carcinoma and is required to sustain FAK steady state levels in breast cancer epithelial cells

Bosch, A., Panoutsopoulou, K., Corominas, J. M., Gimeno, R., Moreno‐Bueno, G., Martín‐Caballero, J., Morales, S., Lobato, T., Martínez‐Romero, C., Farias, E., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1779 · Cited by 31

EZH2 inhibitors-mediated epigenetic reactivation of FOSB inhibits triple-negative breast cancer progress

Zhang, R., Li, X., Liu, Z., Wang, Y., Zhang, H., & Xu, H. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01260-5 · Cited by 31

EZH2 overexpression dampens tumor-suppressive signals via an EGR1 silencer to drive breast tumorigenesis

Guan, X., Deng, H., Choi, U. L., Li, Z., Yang, Y., Zeng, J., Liu, Y., Zhang, X., & Li, G. (2020) · Oncogene · doi:10.1038/s41388-020-01484-9 · Cited by 32

Long Non-Coding RNAs as Potential Diagnostic and Prognostic Biomarkers in Breast Cancer: Progress and Prospects

Lu, C., Wei, D., Zhang, Y., Wang, P., & Zhang, W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.710538 · Cited by 31

Enhancer of Zeste Homolog 2 Overexpression in Nasopharyngeal Carcinoma: An Independent Poor Prognosticator That Enhances Cell Growth

Hwang, C., Huang, H.-Y., Chen, C., Chien, C., Hsu, Y., Li, C., & Fang, F. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.11.062 · Cited by 31

Histone demethylase dUTX antagonizes JAK-STAT signaling to maintain proper gene expression and architecture of the Drosophila testis niche

Tarayrah, L., Herz, H., Shilatifard, A., & Chen, X. (2013) · Development · doi:10.1242/dev.089433 · Cited by 31

Effects of EZH2 Polymorphisms on Susceptibility to and Pathological Development of Hepatocellular Carcinoma

Yu, Y., Su, K. J., Hsieh, Y., Lee, H.-L., Chen, T., Hsiao, P.-C., & Yang, S.-F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074870 · Cited by 31

Pharmacologic down-regulation of EZH2 suppresses bladder cancerin vitroandin vivo

Tang, S., Huang, H., Wu, H.-U., Tsai, Y.-T., Chuang, M., Yu, C., Huang, S.-M., Sun, G.-H., Chang, S.-Y., Hsiao, P., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1867 · Cited by 31

H3K4 Acetylation, H3K9 Acetylation and H3K27 Methylation in Breast Tumor Molecular Subtypes

Judes, G., Dagdemir, A., Karslı-Çeppioğlu, S., Lebert, A., Echegut, M., Ngollo, M., Bignon, Y., Penault-Llorca, F. M., & Bernard-Gallon, D. J. (2016) · Epigenomics · doi:10.2217/epi-2016-0015 · Cited by 31

Trypanocidal activity, cytotoxicity and histone modifications induced by malformin A1 isolated from the marine-derived fungus Aspergillus tubingensis IFM 63452

Notarte, K. I. (2017) · Mycosphere · doi:10.5943/mycosphere/8/1/10 · Cited by 31

Beyond DNA: the Role of Epigenetics in the Premalignant Progression of Breast Cancer

DeVaux, R. S., & Herschkowitz, J. I. (2018) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-018-9414-2 · Cited by 32

Update of research on the role of EZH2 in cancer progression

Shen, L., Cui, Liang, L., Pang, & Liu (2013) · OncoTargets and Therapy · doi:10.2147/ott.s42453 · Cited by 30

Autoregulatory feedback loop of EZH2/miR-200c/E2F3 as a driving force for prostate cancer development

Tao, T., Liu, D., Liu, C., Xu, B., Chen, S., Yin, Y., Ang, L., Huang, Y., Zhang, X., & Chen, M. (2014) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.07.001 · Cited by 30

EZH2 blockade by RNA interference inhibits growth of ovarian cancer by facilitating re-expression of p21waf1/cip1 and by inhibiting mutant p53

Seward, S. M., Semaan, A. Y., Qazi, A. M., Gruzdyn, O. V., Chamala, S., Bryant, C. C., Kumar, S., Cameron, D., Sethi, S. N., Ali‐Fehmi, R., et al. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.04.012 · Cited by 30

Selective inhibition of EZH2 by ZLD10A blocks H3K27 methylation and kills mutant lymphoma cells proliferation

Song, X., Zhang, L., Gao, T., Ye, T., Zhu, Y., Lei, Q., Feng, Q., He, B., Deng, H., & Yu, L. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.04.019 · Cited by 31

Mutations in EZH2 are associated with poor prognosis for patients with myeloid neoplasms

Zhang, Q., Han, Q., Zi, J., Ma, J., Song, H., Tian, Y., McGrath, M., Song, C., & Ge, Z. (2019) · Genes & Diseases · doi:10.1016/j.gendis.2019.05.001 · Cited by 30

ZMYND8 preferentially binds phosphorylated EZH2 to promote a PRC2-dependent to -independent function switch in hypoxia-inducible factor–activated cancer

Tang, B., Sun, R., Wang, D., Sheng, H., Wei, T., Wang, L., Zhang, J., Ho, T. H., Yang, L., Wei, Q., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2019052118 · Cited by 30

ARID1A Mutation in Metastatic Breast Cancer: A Potential Therapeutic Target

Cheng, X., Zhao, J., Dong, F., & Cao, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.759577 · Cited by 31

Phosphorylation and stabilization of EZH2 by DCAF1/VprBP trigger aberrant gene silencing in colon cancer

Ghate, N. B., Kim, S., Shin, Y., Kim, J., Doche, M. E., Valena, S., Situ, A. J., Kim, S., Rhie, S. K., Lenz, H., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37883-1 · Cited by 30

Control of mammary tumor differentiation by SKI-606 (bosutinib)

Hebbard, L., Ceceña, G., Golas, J., Sawada, J., Ellies, L., Charbono, A., Williams, R. M., Jimenez, R. E., Wankell, M., Arndt, K., et al. (2010) · Oncogene · doi:10.1038/onc.2010.412 · Cited by 34

EZH2: novel therapeutic target for human cancer

Li, L. (2014) · Biomedicine · doi:10.7603/s40681-014-0001-6 · Cited by 30

Blockade of CCN6 (WISP3) Activates Growth Factor–Independent Survival and Resistance to Anoikis in Human Mammary Epithelial Cells

Huang, W., Gonzalez, M. E., Toy, K. A., Banerjee, M., & Kleer, C. G. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4225 · Cited by 30

Microchidia protein 2, MORC2, downregulates the cytoskeleton adapter protein, ArgBP2, via histone methylation in gastric cancer cells

Tong, Y., Li, Y., Gu, H., Wang, C., Liu, F., Shao, Y., Li, J., Cao, L., & Li, F. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.10.059 · Cited by 30

SOX5 promotes breast cancer proliferation and invasion by transactivation of EZH2

Sun, C., Ban, Y., Wang, K., Sun, Y., & Zhao, Z. (2019) · Oncology Letters · doi:10.3892/ol.2019.9914 · Cited by 30

Targeting tumour-initiating cells to improve the cure rates for triple-negative breast cancer

Stratford, A. L., Reipas, K. M., Maxwell, C. A., & Dunn, S. E. (2010) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399410001535 · Cited by 30

Identification of polycomb group protein enhancer of zeste homolog 2 (EZH2)‐derived peptides immunogenic in HLA‐A24+ prostate cancer patients

Ogata, R., Matsueda, S., Yao, A., Noguchi, M., Itoh, K., & Harada, M. (2004) · The Prostate · doi:10.1002/pros.20078 · Cited by 30

Targeting EZH2 in Cancer: Mechanisms, Pathways, and Therapeutic Potential

Montani, M. S. G., Benedetti, R., & Cirone, M. (2024) · Molecules · doi:10.3390/molecules29245817 · Cited by 29

EZH2 participates in malignant biological behavior of epithelial ovarian cancer through regulating the expression of BRCA1

Li, T., Cai, J., Ding, H., Xu, L., Yang, Q., & Wang, Z. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.27306 · Cited by 29

β-Arrestin1 promotes the progression of chronic myeloid leukaemia by regulating BCR/ABL H4 acetylation

Qin, R., Li, K., Qi, X.-K., Zhou, X., Wang, L., Zhang, P., & Zou, L. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.335 · Cited by 29

Towards clinically more relevant dissection of patient heterogeneity via survival-based Bayesian clustering

Ahmad, A., & Fröhlich, H. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btx464 · Cited by 32

Salinomycin inhibits epigenetic modulator EZH2 to enhance death receptors in colon cancer stem cells

Singh, A. K., Verma, A., Singh, A., Arya, R. K., Maheshwari, S., Chaturvedi, P., Nengroo, M. A., Saini, K. K., Vishwakarma, A. L., Singh, K., et al. (2020) · Epigenetics · doi:10.1080/15592294.2020.1789270 · Cited by 29

SUMOylation of E2F1 Regulates Expression of EZH2

Du, L., Fakih, M., Rosen, S. T., & Chen, Y. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1259 · Cited by 29

Epigenetic Regulation of Chondrocytes and Subchondral Bone in Osteoarthritis

Ball, H. C., Alejo, A. L., Kronk, T. A., Alejo, A., & Safadi, F. F. (2022) · Life · doi:10.3390/life12040582 · Cited by 29

Recent advances in EZH2-based dual inhibitors in the treatment of cancers

Yang, X., Lu, X., & Li, Y. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115461 · Cited by 30

Identification of PR-SET7 and EZH2 selective inhibitors inducing cell death in human leukemia U937 cells

Valente, S., Lepore, I., Dell’Aversana, C., Tardugno, M., Castellano, S., Sbardella, G., Tomassi, S., Maro, S. D., Novellino, E., Santo, R. D., et al. (2012) · Biochimie · doi:10.1016/j.biochi.2012.06.003 · Cited by 29

The matricellular protein CCN6 (WISP3) decreases Notch1 and suppresses breast cancer initiating cells

Huang, W., Martin, E. E., Burman, B., Gonzalez, M. E., & Kleer, C. G. (2016) · Oncotarget · doi:10.18632/oncotarget.7734 · Cited by 29

Chromatin targeting drugs in cancer and immunityPreprint

Prinjha, R. K., & Tarakhovsky, A. (2013) · Genes & Development · doi:10.1101/gad.221895.113 · Cited by 29

De Novo Peptide Design and Experimental Validation of Histone Methyltransferase Inhibitors

Smadbeck, J. B., Peterson, M. B., Zee, B. M., Garapaty, S., Mago, A., Lee, C., Giannis, A., Trojer, P., Garcia, B. A., & Floudas, C. A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090095 · Cited by 28

mRNA expression levels and genetic status of genes involved in the EGFR and NF-κB pathways in metastatic non-small-cell lung cancer patients

Santarpía, M., Magrí, I., Sanchez-Ronco, M., Costa, C., Molina‐Vila, M. Á., Giménez-Capitán, A. A., Bertrán-Alamillo, J., Mayo, C., Benlloch, S., Viteri, S., et al. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-163 · Cited by 28

Efficacy of EZH2 inhibitory drugs in human papillomavirus-positive and human papillomavirus-negative oropharyngeal squamous cell carcinomas

Lindsay, C., Kostiuk, M. A., Harris, J., O’Connell, D. A., Seikaly, H. R., & Biron, V. L. (2017) · Clinical Epigenetics · doi:10.1186/s13148-017-0390-y · Cited by 28

Antihistamine Drug Ebastine Inhibits Cancer Growth by Targeting Polycomb Group Protein EZH2

Li, Q., Liu, K. Y., Liu, Q., Wang, G., Jiang, W., Meng, Q., Yang, Y., Yang, Y., Wang, R., Zhu, S. L., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0250 · Cited by 28

MicroRNA-1297 regulates hepatocellular carcinoma cell proliferation and apoptosis by targeting EZH2.

Liu, F., He, Y., Shu, R., & Wang, S. (2015) · PubMed Central · Cited by 28

The Role of Polycomb Group Protein EZH2 in Cancer Progression.

Cao, Q. (2008)

Abstract 5309: Understanding the function of EZH2 as a determinant of breast cancer invasion and metastasis

Moore, H. M., Gonzalez, M. E., Daniels, C. N., Li, X., Toy, K. A., & Kleer, C. G. (2012) · Cancer Research · doi:10.1158/1538-7445.am2012-5309

Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer.

Collett, K., Eide, G. E., Arnes, J. B., Stefansson, I. M., Eide, J., Braaten, A. O., Aas, T., Otte, A. P., & Akslen, L. A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1533 · Cited by 272

The Role of EZH2 in Breast Cancer Progression and Metastasis.

Moore, H. M. (2013) · Deep Blue (University of Michigan) · Cited by 2

Understanding the Function of EZH2 as a Determinant of Breast Cancer Invasion and Metastasis

Moore, H. K., & Kleer, C. G. (2013) · doi:10.21236/ada578212